Unexpected hematologic effects of biotherapeutics in nonclinical species and in humans. - Wikidata - wikimedia - TriplyDB

Unexpected hematologic effects of biotherapeutics in nonclinical species and in humans.

Unexpected hematologic effects of biotherapeutics in nonclinical species and in humans.

http://www.wikidata.org/entity/Q38087506

about

Unexpected thrombocytopenia and anemia in cynomolgus monkeys induced by a therapeutic human monoclonal antibody.Severe thrombocytopenia in a patient with hepatitis C treated with eltrombopag from off-label drug use to on-label drug use: a case report.Immunogenicity of therapeutic proteins: influence of aggregation.Reversible bone marrow aplasia induced by pegylated interferon-α-2a therapy in a patient with primary myelofibrosis.Biological Characterization of a Stable Effector Functionless (SEFL) Monoclonal Antibody Scaffold in Vitro.Therapeutic Antibody-Induced Vascular Toxicity Due to Off-Target Activation of Nitric Oxide in Cynomolgus Monkeys.Cetuximab or nimotuzumab plus intensity-modulated radiotherapy versus cisplatin plus intensity-modulated radiotherapy for stage II-IVb nasopharyngeal carcinoma.A Flow-Cytometry-Based Approach to Facilitate Quantification, Size Estimation and Characterization of Sub-visible Particles in Protein Solutions.Engineering an IgG Scaffold Lacking Effector Function with Optimized Developability.

P2860

Q33406359-BFFF4DA7-AB13-48CB-8D05-197192BF1E05 Q33417608-FFC18B0B-1E44-42C6-9E9C-D24ACF90EECE Q38126938-4279BEA9-8CB4-408C-B5C9-34F3EB1AF30C Q38143516-7F8B4D39-02E5-4465-9B71-7C5BED875DF1 Q38725387-D423DE45-4B65-44F6-B320-3B480EC02737 Q39966848-17B620FD-968C-4B66-88F8-086794E1494D Q40174506-F760EF8E-0D90-4E37-8A79-69B6F71F13F1 Q41195349-2BB6EBD0-CDD6-48F7-AE00-E9B4D997617D Q50048248-2395E86A-19DD-443D-8AF0-08F3EA96952E

P2860

Unexpected hematologic effects of biotherapeutics in nonclinical species and in humans.

http://www.wikidata.org/entity/Q38087506

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Unexpected hematologic effects of biotherapeutics in nonclinical species and in humans.

@en

type

label

Unexpected hematologic effects of biotherapeutics in nonclinical species and in humans.

@en

prefLabel

Unexpected hematologic effects of biotherapeutics in nonclinical species and in humans.

@en

P1433

Q38087506-CDB51E02-F1FA-4C49-B86D-EB36A9843876

P1476

Q38087506-1D9E21F3-D2B8-4D54-8D1C-FC3981D496D3

P2093

Q38087506-25ACFBB9-6BF8-426D-9F5E-1D3D00E7DA5A

Q38087506-E13F492D-3007-4D54-8225-FBE2A517E1F9

P2860

Q38087506-00DCC3B0-9D48-4E2B-8834-64BDAE1C8622

Q38087506-011D7309-A718-4C7D-ACBB-96F703342278

Q38087506-0221FB58-5E43-4865-8AAA-5DD9A2E98C63

Q38087506-039E233A-76B4-4F94-ABCD-7EA1C949065F

Q38087506-03E99C31-E7B3-4F15-8872-C023E44F5EE5

Q38087506-04B7F573-4FC4-4474-8362-07EE6258861D

Q38087506-052130A0-CFCD-4F15-9CF9-8A474E2757C8

Q38087506-063559FE-FB2A-42B3-95C2-0D237F6ACF45

Q38087506-06FCDEFE-42EC-47F6-89C8-133D78AD101B

Q38087506-07A01D23-F907-47CF-97CE-1E05866DAF80

P304

Q38087506-5BB37B05-A1AC-46A6-B801-7E372FCD1418

P31

Q38087506-326BC11E-6858-4EA5-AF8A-5BD53E4851DE

P356

Q38087506-F7CE200E-7552-43E3-9200-467399848152

P407

Q38087506-E5635E70-FFE9-4B64-8826-136A29D39A87

P433

Q38087506-4209B31D-AA09-474C-9D51-EA7B38080AB3

P478

Q38087506-CAB09388-4034-44D2-87A1-9E2605F8A0A8

P577

Q38087506-64D1B2DF-B1FC-4DCA-B043-97E68181CBA6

P698

Q38087506-82FFFFFD-0F5E-4A76-9AC3-7869FD2CBFAB

P356

0192623312467400

P1433

Toxicologic Pathology

P1476

Unexpected hematologic effects of biotherapeutics in nonclinical species and in humans.

@en

P2093

Jacqueline M Tarrant

http://www.w3.org/2001/XMLSchema#string

Nancy E Everds

http://www.w3.org/2001/XMLSchema#string

P2860

VEGF inhibition and renal thrombotic microangiopathy

Thrombotic microangiopathy with targeted cancer agents

Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab

Antibodies from patients with heparin-induced thrombocytopenia/thrombosis are specific for platelet factor 4 complexed with heparin or bound to endothelial cells

Genome-wide association study identified ITPA/DDRGK1 variants reflecting thrombocytopenia in pegylated interferon and ribavirin therapy for chronic hepatitis C

Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412

Management and preparedness for infusion and hypersensitivity reactions.

Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3-galactose.

Off-target platelet activation in macaques unique to a therapeutic monoclonal antibody.

Late-onset neutropenia associated with rituximab therapy: evidence for a maturation arrest at the (pro)myelocyte stage of granulopoiesis.

P304

280-302

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1177/0192623312467400

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

41

http://www.w3.org/2001/XMLSchema#string

P577

2013-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23471185

http://www.w3.org/2001/XMLSchema#string